Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire adds Vyvanse to ADHD stable

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Shire's next-generation attention deficit/hyperactivity disorder drug Vyvanse (lisdexamfetamine dimesylate) clears FDA Feb. 23. The company will attempt to transition patients from Adderall XR to the new formulation before 2009, when Adderall generics are likely to launch. Vyvanse received a second "approvable" letter Dec. 21, but Shire had expected approval by March (1Pharmaceutical Approvals Monthly January 2007, p. 16). Indicated to treat children ages six to 12, the drug was evaluated in that age group in three dosage strengths (30 mg, 50 mg and 70 mg) in a 290-patient Phase III randomized, double-blind, placebo-controlled trial. Vyvanse is the first product to be approved following FDA's Feb. 21 announcement that manufacturers of 15 ADHD drugs would need to include patient medication guides to warn of possible cardiovascular and psychiatric risks...

You may also be interested in...



Shire submits Vyvanse sNDA for adult ADHD

After launching Vyvanse (lisdexamfetamine dimesylate) last month, Shire submits a supplemental claim for treatment of attention deficit/hyperactivity disorder in adults, the firm announces June 29. The sNDA will receive a standard review. FDA approved Vyvanse for treatment of ADHD in children ages 6-12 in February 2007 (1Pharmaceutical Approvals Monthly March 2007, In Brief), but as a controlled substance it could not be launched until final Drug Enforcement Administration scheduling. DEA announced its concurrence with FDA's recommendation for Schedule II status on May 3, with an effective date of June 4 (2Pharmaceutical Approvals Monthly June 2007, p. 23). The outcome of the sNDA review could affect Shire's plans for a long-acting adult-targeted version of Adderall XR, SPD465 (triple-beaded mixed amphetamine salts), which received an "approvable" letter in May...

FDA Rejects Favorable Vyvanse DEA Schedule: Time For Shire's 6 p.m. Theme

FDA disagreed with New River Pharmaceuticals (now Shire) on the abuse liability of the d-amphetamine prodrug Vyvanse, forcing the sponsor to change its message from abuse protection to duration of effect - a secondary endpoint in pivotal trials that was not a notable issue in FDA's review of the pediatric attention deficit hyperactivity disorder NDA.

Shire Expects Vyvanse Decision By March – CEO Emmens

Shire anticipates FDA approval of its next-generation attention deficit/hyperactivity disorder treatment Vyvanse (lisdexamfetamine dimesylate) within the next couple of months, Shire CEO Matthew Emmens said Jan. 3

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel